Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Alzheimer’s Drugs Industry?

In the last few years, the market size for Alzheimer’s drugs has experienced significant growth. It is predicted to rise from $9.33 billion in 2024 to $10.09 billion in 2025, displaying a compound annual growth rate (CAGR) of 8.1%. The expansion during the historic period can be traced back to an increase in Alzheimer’s disease incidents, substantial investments in research and development, a better comprehension of disease functions, global health endeavors, as well as public consciousness and education.

The market size for Alzheimer’s medications is anticipated to witness robust expansion in the upcoming years, and it is projected to reach “$14.16 billion in 2029, with a compound annual growth rate (CAGR) of 8.8%.” The predicted growth can be linked to precision medicine strategies, emphasis on disease alteration, identification and validation of biomarkers, patient-centric drug development, and a focus on non-drug interventions. The forecast period is likely to observe key trends such as varied therapeutic approaches, digital health innovations, regenerative medicine, advances in diagnostic technologies, use of artificial intelligence (AI) in drug discovery, along with partnerships and collaborations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

What Forces Are Driving The Growth Of The Alzheimer’s Drugs Industry?

The increasing incidence of Alzheimer’s disease is poised to trigger the expansion of the Alzheimer’s medications market in the future. Alzheimer’s disease, a neurological disorder that progressively worsens, results in the atrophy of the brain and the death of cells. Medications for Alzheimer’s are designed to address memory loss, cognitive issues, and challenges in daily life. Such drugs can significantly improve the life quality and bolster the independence of patients. For illustration, a report from the Alzheimer’s Association, a US-based non-profit committed to Alzheimer’s care, support, and studies, revealed that the count of Americans aged 65 and above diagnosed with Alzheimer’s dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024. Consequently, the escalating incidence of Alzheimer’s is fueling the expansion of the Alzheimer’s medications market.

What Is The Overview Of Market Segmentation In The Alzheimer’s Drugs Industry?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

Subsegments:

1) By Donepezil: Oral Tablets, Oral Solution

2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches

3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules

4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules

What Are The Leading Trends And Opportunities In The Alzheimer’s Drugs Sector?

Leading players in the Alzheimer’s drugs market are pioneering novel solutions such as amyloid plaque-targeting therapy. This therapy aims to push the boundaries of treating Alzheimer’s disease by focusing on the mitigation or prevention of amyloid-beta plaque buildup in the brain. For example, in June 2024, Eli Lilly and Company, a US pharmaceutical firm, gained approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), an organisation committed to safeguarding the nation’s health. Kisunla (donanemab-azbt), the first-ever approved amyloid plaque-targeting therapy for early symptomatic Alzheimer’s disease, functions by assisting the body in eliminating excess amyloid plaques, which are known to contribute to cognitive deterioration in Alzheimer’s disease patients. Kisunla is administered through an intravenous infusion every four weeks. The initial treatment plan involves 700 mg for the first three doses, with an increase to 1400 mg subsequently. Kisunla is specifically prescribed for adults in early stages of Alzheimer’s disease with mild cognitive impairment (MCI) and mild dementia, given they have confirmed amyloid pathology.

Who Are The Primary Players Operating Across The Global Alzheimer’s Drugs Market?

Major companies operating in the alzheimer’s drugs market include AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Which Region Offers The Most Growth Potential For The Alzheimer’s Drugs Market Through 2029?

North Americawas the largest region in the Alzheimer’s drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the Alzheimer’s drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9040&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model